1.41
+0.045(+3.31%)
Currency In USD
| Previous Close | 1.36 |
| Open | 1.38 |
| Day High | 1.46 |
| Day Low | 1.34 |
| 52-Week High | 5.2 |
| 52-Week Low | 1.26 |
| Volume | 2.27M |
| Average Volume | 885,380 |
| Market Cap | 149.78M |
| PE | -3.35 |
| EPS | -0.42 |
| Moving Average 50 Days | 2.07 |
| Moving Average 200 Days | 3.12 |
| Change | 0.05 |
If you invested $1000 in MaxCyte, Inc. (MXCT) since IPO date, it would be worth $82.65 as of August 18, 2025 at a share price of $1.405. Whereas If you bought $1000 worth of MaxCyte, Inc. (MXCT) shares 3 years ago, it would be worth $235.74 as of August 18, 2025 at a share price of $1.405.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MaxCyte Signs Platform License Agreement with Adicet Bio
GlobeNewswire Inc.
Aug 04, 2025 12:05 PM GMT
MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engi
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
GlobeNewswire Inc.
Jul 31, 2025 12:05 PM GMT
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapiesROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused c
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire Inc.
Jul 09, 2025 12:05 PM GMT
ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cel